Tower Research Capital (TRC)’s Windtree Therapeutics WINT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-2,212
| Closed | -$1.14K | – | 5680 |
|
|
2025
Q2 | $1.14K | Buy |
2,212
+836
| +61% | +$741 | ﹤0.01% | 4867 |
|
|
2025
Q1 | $1.73K | Buy |
1,376
+1,286
| +1,429% | +$7.93K | ﹤0.01% | 4657 |
|
|
2024
Q4 | $1.58K | Buy |
90
+51
| +131% | +$1.62K | ﹤0.01% | 4998 |
|
|
2024
Q3 | $4.64K | Buy |
39
+9
| +30% | +$2.72K | ﹤0.01% | 4465 |
|
|
2024
Q2 | $4.83K | Buy |
+30
| New | +$7.04K | ﹤0.01% | 4741 |
|
|
2023
Q4 | – | Sell |
-11
| Closed | -$9.18K | – | 6198 |
|
|
2023
Q3 | $9.18K | Buy |
11
+3
| +38% | +$3.32K | ﹤0.01% | 4252 |
|
|
2023
Q2 | $9.03K | Buy |
8
+7
| +700% | +$14.2K | ﹤0.01% | 4341 |
|
|
2023
Q1 | $6K | Buy |
+1
| New | +$6.7K | ﹤0.01% | 4890 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 5246 |
|
|
2022
Q3 | – | Sell |
-1
| Closed | -$17.9K | – | 5071 |
|
|
2022
Q2 | $12K | Buy |
+1
| New | +$29.5K | ﹤0.01% | 4321 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 5120 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 5896 |
|
|
2021
Q3 | – | Sell |
-1
| Closed | -$62K | – | 6225 |
|
|
2021
Q2 | $62K | Buy |
+1
| New | +$97.3K | ﹤0.01% | 2843 |
|
|
2021
Q1 | – | Hold |
0
| – | -$19K | – | 5770 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 3908 |
|
Tower Research Capital (TRC)'s WINT Position: Q3 2025 in Review
Tower Research Capital (TRC) sold out of Windtree Therapeutics (WINT) in Q3 2025, closing a stake of 2,212 shares — an estimated $1.14K sold.
Tower Research Capital (TRC) first reported a position in WINT in Q2 2021 and held it in 10 quarters. The position peaked at $62K in Q2 2021. 0 funds tracked by Wall St. Rank hold WINT as of Q3 2025.
- Tower Research Capital (TRC) reported no remaining Windtree Therapeutics position as of Q3 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 2,212 Windtree Therapeutics shares in Q3 2025, an estimated $1.14K.
- Tower Research Capital (TRC) first reported a position in Windtree Therapeutics in Q2 2021 and held it in 10 quarters.
- Tower Research Capital (TRC)'s Windtree Therapeutics position peaked at $62K in Q2 2021.
- 0 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q3 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.